C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Total Debt

Short-term and long-term borrowings combined.

C4 Therapeutics, Inc.NASDAQ: CCCC

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 9.2% from a year ago

Total debt stood at $58.45M at the end of Q1 FY2026, down 9.2% from a year earlier and down 2.6% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Total debt amounted to 17.8% of total assets at the end of Q1 FY2026, down 2.4 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -9.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$58.45M-2.6% QoQ
Last fiscal yearDec 2025
$59.98M-8.8% YoY
Year agoMar 2025
$64.37M-9.2% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.2%——
1 year-8.8%——
3-year CAGR-11.7%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
59.98M USD
Year-over-year change
-8.8%
4-year CAGR
+8.8%

Total Debt vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -9.2% is the 5th highest of 9, against a peer median of +6.6%.
  • Total debt amounts to 17.8% of total assets for CCCC, versus a peer median of 21.4%.
CCCC Competitors
Total Debt for CCCC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARMPArmata Pharmaceuticals, Inc.Mar 2026$373.67M USD+177.5%+80.7%535.3%
MISTMilestone Pharmaceuticals Inc.Mar 2026$137.33M USD+147.1%+186.2%70.9%
CDXSCodexis, Inc.Mar 2026$72.9M USD+22.5%+18.8%56.4%
CCCCC4 Therapeutics, Inc.Mar 2026$58.45M USD-9.2%-11.7%17.8%
OABIOmniAb, Inc.Mar 2026$19.67M USD-12.5%-7.6%6.7%
SGMOSangamo Therapeutics, Inc.Mar 2026$19.33M USD-22.3%-14.7%32.2%
PEPGPepGen Inc.Mar 2026$16.56M USD-9.4%-11.5%10.6%
MOLNMolecular Partners AGMar 2026CHF 3.33M CHF+55.7%-9.1%3.8%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$3.07M USD-11.8%-0.4%7.6%
Peer median (excluding CCCC) —+6.6%-4.0%21.4%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.12M29.75M126.59M55.5M74.6M
Short-term Investments233.16M246.4M127.09M189.41M173.93M
Net Receivables5.72M1.47M11.8M3.1M2.4M
Inventory0(60.96M)000
Other Current Assets070.89M5.71M9.76M7.17M
Total Current Assets325.69M287.56M271.19M257.77M258.11M
Property, Plant & Equipment (Net)35.05M77.52M71.09M63.38M45.28M
Goodwill00000
Intangible Assets00000
Long-term Investments142.2M60.96M28.01M22.36M48.56M
Tax Assets00000
Other Non-current Assets3.82M4.81M6.17M6.1M7.13M
Total Non-current Assets181.08M143.28M105.26M91.84M100.97M
Total Assets506.77M430.84M376.45M349.6M359.08M
Account Payables4.51M1.17M1.45M1.33M858K
Short-term Debt02.29M000
Tax Payables00000
Deferred Revenue31.8M16.62M15.47M18.71M12.49M
Other Current Liabilities5.5M3.11M9.39M9.3M10.06M
Total Current Liabilities51.25M44.55M42.77M45.18M33.03M
Long-term Debt10.77M9.2M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)24.37M16.9M21.81M28.46M15.84M
Other Non-current Liabilities00000
Total Non-current Liabilities65.91M97.06M87.57M88.44M69.46M
Total Liabilities117.16M141.61M130.34M133.62M102.49M
Common Stock5K5K6K7K9K
Retained Earnings(267.72M)(395.89M)(528.38M)(633.7M)(738.69M)
Accumulated OCI(775K)(4.14M)(127K)53K50K
Other Stockholders Equity00000
Minority Interest00000
Total Equity389.61M289.23M246.11M215.99M256.59M
Total Debt42.88M87.15M70.98M65.76M59.98M
Net Debt(33.25M)57.4M(55.61M)10.26M(14.62M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.